Gastro Education 2018
Journal of Clinical Gastroenterology and Hepatology
ISSN: 2575-7733
Page 61
September 06-07, 2018
London, UK
14
th
International Conference on
Gastro Education
Introduction:
Novel immunotherapy strategies that may be
employedtorenderacancermoreimmunogenic,generateantigen-
speci c or nonspeci c immune activation, and/or manipulate the
tumor micro-environment. A number of immunotherapeutic trials
have been performed to evaluate the ef cacy of immunotherapy
for the treatment of HCC (hepatocellular carcinoma). Ambovex
is a botanical medicine derived from the plants belonging to the
family Ranunculaceae and having immune-modulating effect. In
this pilot study we used Ambovex as an immunotherapy trial for
treating Egyptian patients with unresectable HCC.
Patients & Methodology:
We included 148 patients with post-
HCV liver cirrhosis and HCC. Their HCC was diagnosed by
Ultrasound/CT and AFP >400 ngm and was un t for any of the
available treatment modalities. They were divided into 2 groups:
group 1 (88 patients) for treatment and group 2 (60 patients) as
a control group. After getting their informal consent, we gave for
group 1 Ambovex sublingual oral spray (20 buffs sublingual tid)
for 4 months. For group 2, sub- lingual glucose-saline sublingual
spray as a placebo. Both groups were followed up for one year.
Results:
There were no side effects apart from taste changes in
25% of patients in group I. In group I there was tumor regression
and signi cant decrease in AFP in 36 patients (40.9%), and 25
patients (28.4%) showed stable tumor size and AFP level and
27 patients (30.7%) showed disease progression. In group II, no
patients showed tumor stabilization. At one year follow-up 61
patients (69.3%) were still living in group I compared to only 21
patients (35%) in group II.
Conclusions:
From this pilot study, we could conclude that
Ambovex with its immune- modulating effect have initial
promising results in treating Egyptian patients with HCC. Further
controlled, randomized, multicenter studies are needed to con rm
these results.
hsalama888@yahoo.comAmbovex oral sublingual spray as immuno-therapy trial for
HCC among Egyptian patients
Hosny Salama, Hassan Ahmed, Ismail, Elchagea, Abdel Rahman Zekri, Eman
Medhat, Midhead Lange, Mohamed Rabbat
and
Pravin Pumamiya
1
National Cancer Institute - Cairo University, Egypt
J Clin Gastroenterol Hepatol 2018, Volume 2
DOI: 10.21767/2575-7733-C2-006




